Epstein Secrets

r 2020 and 2021. Some lawmakers expressed concern that a rift among White House advisers could imperil the deal at a final stage of negotiations. (Damian Paletta, Erica Werner and Yasmeen Abutaleb) 3. A federal judge said he is skeptical that there is enough evidence to convict Michael Flynn's former busine

xpressed concern that a rift among White House advisers could imperil the deal at a final stage of negotiations. (Damian Paletta, Erica Werner and Yasmeen Abutaleb) 3. A federal judge said he is skeptical that there is enough evidence to convict Michael Flynn's former business partner of illegally lobbying for

or 2020 and 2021. Some lawmakers expressed concern that a rift among White House advisers could imperil the deal at a final stage of negotiations. (Damian Paletta. Erica Werner and Yasmeen Abutaleb) 3. A federal judge said he is skeptical that there is enough evidence to convict Michael Flynn's former busine

expressed concern that a rift among White House advisers could imperil the deal at a final stage of negotiations. (Damian Paletta. Erica Werner and Yasmeen Abutaleb) 3. A federal judge said he is skeptical that there is enough evidence to convict Michael Flynn's former business partner of illegally lobbying fo

t two or three weeks, jolted by a recent report that found the Treasury Department was running out of cash much faster than previously forecasted," Damian Paletta and Erica Werner report. "But the talks have bogged down amid acrimony between Democrats and the White House, and now Washington's leaders run the

o middlemen in Medicare, which Trump's top health official had touted as one of the most significant changes to curb medicine costs for consumers. Yasmeen Abutaleb reports: "The rule is the second major drug pricing effort to get blocked this week, complicating the administration's efforts to make lowering pr

t two or three weeks, jolted by a recent report that found the Treasury Department was running out of cash much faster than previously forecasted," Damian Paletta and Erica Werner report. "But the talks have bogged down amid acrimony between Democrats and the White House, and now Washington's leaders run the

o middlemen in Medicare, which Trump's top health official had touted as one of the most significant changes to curb medicine costs for consumers. Yasmeen Abutaleb reports: "The rule is the second major drug pricing effort to get blocked this week, complicating the administration's efforts to make lowering pre